Aims: The aorta in Marfan syndrome (MFS) patients is variably affected. We investigated the assumed genotype-effect on protein production as a risk factor for a severe aortic phenotype in adult MFS patients.
Introduction
Marfan syndrome (MFS) is a connective tissue disorder caused by mutations in the FBN1 gene encoding the fibrillin-1 protein, a structural component of elastic fibres in the tunica media in large arteries. 1 Mortality and morbidity is mainly determined by the development of an aortic aneurysm and subsequent dissection. 2 Prophylactic aortic surgery has increased survival and is currently relatively uniformly incorporated in clinical management of MFS patients at certain threshold values of aortic diameter. 3 The current guidelines recommend that patients should undergo prophylactic aortic surgery when the aortic maximal diameter is >50 mm, or at 46-50 mm with a family history of aortic dissection, progressive dilation >2 mm/year as confirmed by repeated measurement, severe aortic or mitral valve regurgitation, or with a desire of pregnancy. 3 However, the observation of both very large undissected aneurysms in MFS, and the occurrence of dissection below surgical thresholds, raise suspicion that more risk factors are necessary to reliably predict aortic dissection. 4 Although MFS is being considered monogenetic in nature, a multitude of mutations (>2900 currently known) in the large FBN1 gene (>200 kb, 65 exons) lead to a very heterogeneous vascular phenotype. 5 Recently, we demonstrated that we were able to predict the effect of the FBN1 mutation on fibrillin-1 protein: 1) mutations resulting in deficient fibrillin-1 protein, where mainly the non-mutated allele is expressed (called haploinsufficient (HI) mutations), and 2) mutations resulting in abnormal fibrillin-1 formation interacting with normal fibrillin-1 derived from the non-mutated allele (called dominant-negative (DN) mutations). 6 However, the influence of this classification on mortality and aortic dissection, is still unknown. Accordingly, the aim of this study was to retrospectively assess the impact of FBN1 mutation type (HI versus DN) upon prospective outcome, including survival and dissection-free survival in MFS patients.
Methods

Patient population
The CONgenital CORvitia (CONCOR) Dutch national registry database, started in January 2001, aims to facilitate research into the aetiology of congenital heart disease and on its outcome. 7 The registry complied with the Declaration of Helsinki and written informed consent was obtained from all participants. In CONCOR, all patients with congenital heart disease aged 18 years or older have been recruited and included by three independent, permanently employed research nurses. Currently, 107 Dutch hospitals are participating, including all eight tertiary referral centres from which 65% of patients originate. An estimated 35-50% (over 15,000 patients) of the total adult congenital heart disease 90 population in the Netherlands is registered in CONCOR. Between 2001 and 2014, 570 patients aged 18 years or older were included in CONCOR diagnosed as having MFS by one of the four Dutch multidisciplinary screening teams. Diagnosis was performed according to the Ghent criteria during the period 1996-2010 and according to the revised Ghent criteria thereafter. 8, 9 In December 2014 we updated the CONCOR registry with aortic complications and type of the FBN1 mutation, when available.
Mutation classification
Sanger sequencing of the 65 coding FBN1 exons in genomic DNA from blood cells was used to detect mutations. Large deletions were tested with multiplex ligationdependent probe amplification (MRC-Holland, MLPA kit P065 and P066). All known pathogenic FBN1 mutations were classified into HI mutations or DN mutations as described previously. 6 In short, HI mutations lead to production of a reduced amount of normal functioning fibrillin-1 protein (derived from the non-mutated allele), since the mutations cause protein degradation, nonsense mediated decay or prevent protein translation, mostly by premature termination codon mutations and frameshift mutations. 10, 11 DN mutations lead to stable mutant fibrillin-1 protein with altered structure or a shorter but stable fibrillin-1 protein, mostly by missense mutations and exon-skipping mutations. 12, 13 Mutant fibrillin-1 forms a matrix together with normal fibrillin-1 protein (derived from the non-mutated allele). Skin biopsies were taken from all patients with a splice site mutation, in order to study mRNA to differentiate between nonsense mediated decay or an in-frame event.
Endpoints
Primary endpoints were death and aortic dissection. Patients were followed from date of inclusion in the CONCOR registry until date of dissection or date of death. Aortic dissection was defined as any dissection (type A and type B) in the aorta confirmed with an imaging modality. Patients were censored at January 1st of 2015. Secondary endpoint was aortic surgery. The decision to perform aortic surgery was completely at the discretion of the attending 'Heart team' , based on guidelines. 3 Complication-free survival was defined as the time-interval between date of inclusion in CONCOR registry and date of first event (death, aortic dissection, aortic surgery).
Statistical analysis
Data are presented as mean value ± standard deviation and first to third quartile (Q1-Q3) or as number of patients (percent). Comparisons between continuous variables were made by Student's T test. Comparisons between categorical variables were made by Fisher's exact tests. Cox-regression analysis was used to analyse survival, dissection-free survival and complication-free survival during follow-up. Cox-regression was corrected for aortic dissection and aortic surgery before inclusion in CONCOR and for sex and age at baseline, since these factors were found to influence the event rate. All statistical tests were two-sided and differences were considered statistically significant at p < 0.05. Data analysis was performed using the SPSS statistical package (20.0 for windows; SPSS Inc., Chicago, Illinois, USA).
Results
Baseline Characteristics
A total of 570 MFS patients, mean age 36.5±13.5 years (Q1-Q3: 25 -47 years), were registered in the Dutch CONCOR registry since January 2001, 30.9% of the patients were known with at least one aortic complication at time of inclusion: aortic dissection (8.2%) and aortic surgery (28.9%). Sex was equally distributed in the total cohort with 51.2% males. Men had a history of aortic surgery before inclusion in CONCOR more frequently (38.0% men versus 19.4% women, p<0.001). There was no sex difference in the medical history of aortic dissections (8.9% men versus 7.6% women, p=0.648).
High survival and dissection-free survival in patients with Marfan syndrome
After a mean follow-up of 8.2 years (Q1-Q3: 6.0-11.0 years), a total of 161 patients (28.2%) developed one or more complications (cardiovascular death, aortic dissection or aortic surgery). Five-year and ten-year cumulative survival was 96.9% and 93.8%, respectively. After five and ten years, dissection-free survival was 92.9% and 84.2%, respectively ( Figure 1 ). FBN1 mutation analysis was performed in 433 patients (76%); 357 pathogenic FBN1 mutations (82.4%) were found in the patients included in the CONCOR registry. In the 357 patients carrying a pathogenic FBN1 mutation, cumulative survival and dissection-free survival were similar to the total cohort (cumulative survival was 97.3% after five-year and 92.5% after ten-year; dissection-free survival was 93.6% after five-year and 83.7% after ten-year). Of the remaining 213 reported MFS patients fulfilling the Revised Ghent criteria, in 65 patients (11.4%) no FBN1 mutation was shown after recent analysis, 4 had a TGFBR1 mutation, 4 had a TGFBR2 mutation, 1 had a TGFB2 mutation, 2 had an SMAD3 mutation and 1 had an MYH11 mutation and in 136 (24%) patients no analysis 92 was performed. Table 1 shows the differences in event rate between patients with an FBN1 mutation, confirmed no mutation, mutation in a different gene and no mutation analysis performed.
Patients with previous aortic complications are at increased risk for novel aortic complications
Patients with an aortic dissection before inclusion in CONCOR (n=47, mean age: 45.6 years (Q1-Q3: 37.0-53.0 years), 55% men) were at increased risk for the combined clinical endpoint aortic dissection, cardiovascular mortality and surgery (HR: 1.9, 95%CI: 1.2-3.1, p=0.005), for the combined clinical endpoint aortic dissection and cardiovascular mortality (HR: 2.8, 95%CI: 1.6-4.9, p<0.001), and demonstrated an increased risk for cardiovascular mortality (HR: 3.8, 95%CI: 1.7-8.3, p=0.001).
Patients with an aortic root replacement before inclusion in CONCOR (n=165, mean age: 38.4±13.3 years (Q1-Q3: 27.0-49.0 years), 67% men) were at increased risk for the combined clinical endpoint aortic dissection, cardiovascular mortality and surgery (HR: 1.6, 95%CI: 1.1-2.2, p=0.005), for the combined clinical endpoint aortic dissection and cardiovascular mortality, (HR: 3.4, 95%CI: 2.2-5.2, p<0.001), and demonstrated a trend towards increased risk of cardiovascular mortality (HR: 1.9, 95%CI: 1.0-3.9, p=0.057). 
Patients with a haploinsufficiency mutation are at increased risk for aortic complications
Classification of mutations revealed that 146 patients (40.9%) were positive for a HI mutation and 211 patients (59.1%) were positive for a DN mutation. The Supplemental Table 1 demonstrates all HI mutations and Supplemental Table 2 shows the DN mutations. Baseline characteristics were similar between the two groups ( Cox-regression analysis was adjusted by prior aortic dissection, prior aortic surgery, sex and age at baseline, since these factors were found to influence the event rate. HI patients had a 2.5-fold increased risk for cardiovascular death as compared with DN patients (adjusted HR: 2.5, 95%CI: 1.0-6.1, p=0.049, Figure 2A) . HI patients had a 2.4-fold increased risk for the combined clinical endpoint cardiovascular death and aortic dissection (adjusted HR: 2.4, 95%CI: 1.4-4.2, p<0.001, Figure 2B) , and a 1.6-fold increased risk for any cardiovascular event (adjusted HR: 1.6, 95%CI 1.1-2.3, p=0.014). We provided the uncorrected HR as well as the adjusted HR noted above in Table 3 Figure 2 . (A) Cumulative mortality rate and (B) mortality and / or dissection rate of patients with a FBN1 mutation leading to a dominant negative effect (DN, red dotted line) and patients with a mutation leading to haploinsufficiency (HI, blue line). The hazard ratios shown are adjusted for sex, age at inclusion, and presence of aortic dissection and aortic surgery at baseline. 
Discussion
This is the first study to demonstrate that FBN1 mutation type has a major impact on survival in adults with MFS. Our study shows that HI patients have a 2.5-fold higher risk of cardiovascular death, a 2.4-fold increased risk of meeting the combined endpoint comprising death or dissection and a 1.6-fold higher risk of any aortic complication after a mean follow-up of 8.2 years compared with DN patients. Prognosis in MFS is mainly determined by progressive dilation of the aorta leading to aortic dissection or rupture, which is the major cause of death. Although phenotypegenotype relations have been investigated extensively in the past decades, genotype has never been shown to be of importance in survival of MFS patients. 3 In this study,
we evaluated the effects of FBN1 mutation type on morbidity and mortality in a large cohort of adults MFS patients. Despite a low mortality rate, patients with a HI mutation were at increased risk for cardiovascular death, aortic dissection or the combined clinical endpoint, when compared to DN patients (59.1% of the patients with a pathogenic FBN1 mutation). The percentage of patients having a HI mutation (40.9%) in this study reveals that FBN1 HI comprises a substantial part of the adult MFS population, similar to our previous study population in the COMPARE cohort, 6 and similar to the mutations included in the Universal Mutation Database for FBN1 mutations. 5, 14 It is commonly thought that patients with a HI mutation have a milder phenotype due to nonsense mediated decay, compared to patients with a DN mutation. 15 However, several studies have shown that HI patients seem to have a more severe vascular phenotype compared to DN patients. 5, 6, 10, 11 Furthermore, Baudhuin and colleagues recently demonstrated that aortic complications more frequently occurred in a small cohort of MFS patients with a nonsense or frameshift mutations (HI mutation), 16 suggesting that the effect of the FBN1 mutation on fibrillin-1 protein synthesis partly determines MFS phenotype. In the present study, we retrospectively confirmed in a large cohort that patients with a HI mutation are at increased risk for "hard clinical endpoints", including aortic dissection and mortality. Currently, there is no definite explanation for a more severe vascular phenotype in HI patients. In the well-known FBN1 (C1039G) mouse model, the dominant negative mutation leads to characteristics of the Marfan phenotype, i.e. aortic dilation and skeletal deformity. 17 However, addition of a wild-type FBN1 transgene to this FBN1 (C1039G) mouse model, rescues the aortic phenotype. 18 This indicates that limited amount of normal fibrillin-1 rather than production of mutant protein is the primary determinant of failed microfibrillar assembly. Further evidence for this hypothesis is provided by a recent study where the level of WT FBN1 expression in HI patients was inversely correlated with aortic root size. 19 In addition, one older study with smaller numbers already published in 1995 revealed that mutations leading to a smaller amount of fibrillin-1 protein was associated 96 with a shortened event-free survival and more severe cardiovascular complications. 20 This study underscores the relation between survival and type of FBN1 mutation. Notably, men had more frequently a history of aortic surgery before inclusion in CON-COR compared to women, and men were at increased risk to undergo aortic surgery during follow-up as well. Since men are not at increased risk for aortic dissections or cardiovascular mortality, the increased risk for aortic surgery may be due to the absolute threshold for aortic surgery (45-50 mm) and the fact that men overall have a larger body surface area. 3 In other studies, more genetic subgroups with a genotype-phenotype association have been investigated. For example, cysteine substitutions have been associated with ectopia lentis. In addition, Kuhne et al, and Aydin et al, differentiated DN-FBN1 mutations based on their location in the FBN1 gene, i.e. mutations in calcium-binding EGF-domains or in the TB-domains, and their correlations with mitral valve disease and ventricular arrhythmia. 21, 22 However, the impact of these associations on survival has not been assessed. The most striking association between survival and genotype has been found in neonatal MFS, caused by mutations in exons 24-32. 23 Neonatal MFS is rare and often lethal due to heart failure at a very young age. In our opinion, this condition should be regarded as a specific entity. In the multitude of FBN1 mutations, we have now applied a relatively simple method, based on the effect of the mutation on FBN1 protein synthesis, to discriminate between more and less affected (groups of ) MFS patients. Further subclassification of the patients with a DN-FBN1 mutation may be an important next step in order to enlighten the genotype-phenotype correlations within the different types of DN-FBN1 mutations, such as attempted by Kuhne and Aydin. 21, 22 Another interesting differentiation of DN-FBN1 mutations might be the type of FBN1 mutation (i.e. cysteine substitution versus exon skipping mutations). For these types of classifications, much larger patient cohorts are necessary and international cooperation should be encouraged. The present study has several limitations. First, patients with the most severe cardiovascular phenotype, who died before adulthood, are not accounted for in this study. Second, patients with a FBN1 mutation, yet not fulfilling the Ghent criteria are not included in CONCOR. In addition, diagnosis was performed according to the Ghent criteria during the period 1996-2010 and according to the revised Ghent criteria thereafter, which may have introduced some bias, since in the revised Ghent criteria more weight has been given to genetic analysis. Third, only few patients have died during follow-up, thus mortality analyses are based on a small number of patients. Fourth, in only 76% of the patients, mutation analysis was performed; others refused mutation analysis or analysis was not considered necessary for diagnosis and counselling. Finally, our classification of missense mutations as DN is not completely validated, because some mutations may lead to unstable protein and HI. We tested splice site mutations on skin biopsies, however, we have not tested protein stability. Consequently, among our DN classified samples some may actually have a HI effect due to protein degradation. Despite this possible misclassification in a small number of cases, our approach lead to surprising data.
In conclusion, MFS patients with a HI mutation are at increased risk for cardiovascular death and aortic dissection compared to DN patients. The results of this study, in combination with the available evidence so far, implicate that patients with a reduced amount of fibrillin-1 protein have a worse prognosis. Currently, genetic screening is only part of the diagnostic process and not standardly performed in all patients. As suggested by our preliminary results, genotype could be of great importance for patient management and thus change clinical guidelines and reimbursement strategies of insurance companies. For optimal assessment of prognosis and treatment of MFS patients, more research upon genetic screening, and clinical evaluation is warranted.
